PT-141 (Bremelanotide)

Overview

PT-141 (bremelanotide) is a melanocortin receptor agonist that acts on central nervous system pathways involved in sexual desire and arousal — a different mechanism from blood-flow drugs like sildenafil. It is FDA-approved under the brand name Vyleesi (approved 2019) for hypoactive sexual desire disorder (HSDD) in premenopausal women, with a labeled dose of 1.75 mg subcutaneously at least 45 minutes before anticipated activity (no more than one dose per 24 hours and no more than 8 doses per month). It is also used off-label and compounded for other populations. A transient increase in blood pressure (and decrease in heart rate) is a documented effect to monitor.

Commonly Reported Uses

These are uses commonly discussed or marketed by users and vendors — not a list of proven or approved benefits, and not a recommendation.

• Hypoactive sexual desire disorder (HSDD) in premenopausal women (FDA-approved as Vyleesi)
• Libido / sexual arousal support in other populations — off-label / compounded, not an approved use
• Discussed for erectile dysfunction in men — research/off-label, not an approved use

What to Track

Data points you and your clinician might monitor. For observation only — not a diagnostic protocol.

• Blood pressure and heart rate — documented transient BP increase after dosing; monitor especially if cardiovascular risk factors exist
• Subjective — desire/arousal and satisfaction; nausea (a common side effect); flushing
• Skin — note any pigmentation changes (melanocortin pathway)

Sources & References

1. [1]FDA — Vyleesi (bremelanotide) approval and prescribing information
2. [2]PT-141 / bremelanotide mechanism and FDA status — Regen Doctors
3. [3]PT-141 bremelanotide guide 2026 — evidence, FDA status, dosing — Telehealth Ally